Anti-cancer effects of a new docosahexaenoic acid monoacylglyceride in lung adenocarcinoma

Recent Patents on Anti-Cancer Drug Discovery

Volumn 8, Issue 3, 2013, Pages 319-334

  Morin, Caroline ^a,b   Fortin, Samuel ^a   Cantin, André M ^b   Sirois, Marco ^b   Sirois, Chantal ^b   Rizcallah, Edmond ^b   Rousseau, Éric ^b  

^a SCF Pharma   (Canada)

^b UNIVERSITÉ DE SHERBROOKE   (Canada)

Author keywords

Apoptosis; COX 2; DHA; Lung adenocarcinoma; PTEN

Indexed keywords

CASPASE 3; CYCLOOXYGENASE 2; DOCOSAHEXAENOIC ACID; DOCOSAHEXAENOIC ACID MONOACYLGLYCERIDE; DOCOSAPENTAENOIC ACID; I KAPPA B ALPHA; ICOSAPENTAENOIC ACID; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MYC PROTEIN; PHOSPHATIDYLINOSITOL 3, 4, 5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN BCL 2; PROTEIN KINASE B; TRANSCRIPTION FACTOR RELA; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ADULT; AGED; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CELL PROLIFERATION; CLINICAL ARTICLE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; HUMAN TISSUE; IC 50; IMMUNOFLUORESCENCE; IMMUNOHISTOCHEMISTRY; LUNG ADENOCARCINOMA; MALE; MASS SPECTROMETRY; MOUSE; NICK END LABELING; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; TUMOR GROWTH; TUMOR VOLUME; TUMOR XENOGRAFT; WESTERN BLOTTING;

ADENOCARCINOMA; ADMINISTRATION, ORAL; AGED; ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL LINE, TUMOR; CELL PROLIFERATION; CYCLOOXYGENASE 2; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MICE; MICE, NUDE; MIDDLE AGED; MONOGLYCERIDES; NF-KAPPA B; PHOSPHORYLATION; PROTO-ONCOGENE PROTEINS C-AKT; PTEN PHOSPHOHYDROLASE; TIME FACTORS; TUMOR CELLS, CULTURED; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84882752446     PISSN: 15748928     EISSN: None     Source Type: Journal    
DOI: 10.2174/1574891X113089990032     Document Type: Article

References (86)

1. Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin 2010; 60(5): 277-300.
2. Herbst RS, Heymach JV, Lippman SM. Lung cancer. N Engl J Med 2008; 359(13): 1367-80.
3. Fradet V, Cheng I, Casey G, Witte JS. Dietary omega-3 fatty acids, cyclooxygenase-2 genetic variation, and aggressive prostate cancer risk. Clin cancer Res 2009; 15(7): 2559-66.
4. Gleissman H, Johnsen JI, Kogner P. Omega-3 fatty acids in cancer, the protectors of good and the killers of evil? Exp cell Res 2010; 316(8): 1365-73.
5. Krishnamoorthy S, Honn KV. Eicosanoids in tumor progression and metastasis. Subcell Biochem 2008; 49: 145-68.
6. Martin DD, Robbins ME, Spector AA, Wen BC, Hussey DH. The fatty acid composition of human gliomas differs from that found in nonmalignant brain tissue. Lipids 1996; 31(12): 1283-8.
7. Reynolds LM, Dalton CF, Reynolds GP. Phospholipid fatty acids and neurotoxicity in human neuroblastoma SH-SY5Y cells. Neurosci Lett 2001; 309(3): 193-6.
8. Courtney ED, Matthews S, Finlayson C, Di Pierro D, Belluzzi A, Roda E, et al. Eicosapentaenoic acid (EPA) reduces crypt cell proliferation and increases apoptosis in normal colonic mucosa in subjects with a history of colorectal adenomas. Int J Colorectal Dis 2007; 22(7): 765-76.
9. Smith-Warner SA, Spiegelman D, Ritz J, Albanes D, Beeson WL, Bernstein L, et al. Methods for pooling results of epidemiologic studies: the Pooling Project of Prospective Studies of Diet and Cancer. Am J Epidemiol 2006; 163(11): 1053-64.
10. Thiebaut AC, Chajes V, Gerber M, Boutron-Ruault MC, Joulin V, Lenoir G, et al. Dietary intakes of omega-6 and omega-3 polyunsaturated fatty acids and the risk of breast cancer. Int J Cancer 2009; 124(4): 924-31.
11. Larsson SC, Kumlin M, Ingelman-Sundberg M, Wolk A. Dietary long-chain n-3 fatty acids for the prevention of cancer: A review of potential mechanisms. Am J Clin Nutr 2004; 79(6): 935-45.
12. Ghosh-Choudhury T, Mandal CC, Woodruff K, St Clair P, Fernandes G, Choudhury GG, et al. Fish oil targets PTEN to regulate NFkappaB for downregulation of anti-apoptotic genes in breast tumor growth. Breast Cancer Res Treat 2009; 118(1): 213-28.
13. Calviello G, Serini S, Piccioni E, Pessina G. Antineoplastic effects of n-3 polyunsaturated fatty acids in combination with drugs and radiotherapy: Preventive and therapeutic strategies. Nutr Cancer 2009; 61(3): 287-301.
14. Manna S, Chakraborty T, Ghosh B, Chatterjee M, Panda A, Srivastava S, et al. Dietary fish oil associated with increased apoptosis and modulated expression of Bax and Bcl-2 during 7, 12-dimethylbenz(alpha)anthracene-induced mammary carcinogenesis in rats. Prostaglandins Leukot Essent Fatty Acids 2008; 79(1-2): 5-14.
15. Serini S, Piccioni E, Merendino N, Calviello G. Dietary polyunsaturated fatty acids as inducers of apoptosis: Implications for cancer. Prostaglandins Leukot Essent Fatty Acids 2009; 14(2): 135-52.
16. Chen W, Li Z, Bai L, Lin Y. NFkappaB in lung cancer, a carcinogenesis mediator and a prevention and therapy target. Front Biosci 2011; 16: 1172-85.
17. Shen HM, Tergaonkar V. NFkappaB signaling in carcinogenesis and as a potential molecular target for cancer therapy. Apoptosis 2009; 14(4): 348-63.
18. Baud V, Karin M. Is NFkappaB a good target for cancer therapy? Hopes and pitfalls. Nat Rev Drug Discov 2009; 8(1): 33-40.
19. Perkins ND. The diverse and complex roles of NFkappaB subunits in cancer. Nat Rev Cancer 2012; 12(2): 121-32.
20. Hida T, Yatabe Y, Achiwa H, Muramatsu H, Kozaki K, Nakamura S, et al. Increased expression of cyclooxygenase-2 occurs frequently in human lung cancers, specifically in adenocarcinomas. Cancer Res 1998; 58(17): 3761-4.
21. Wolff H, Saukkonen K, Anttila S, Karjalainen A, Vainio H, Ristimaki A. Expression of cyclooxygenase-2 in human lung carcinoma. Cancer Res 1998; 58(22): 4997-5001.
22. Steinbach G, Lynch PM, Phillips RK, Wallace MH, Hawk E, Gordon GB, et al. The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis. N Engl J Med 2000; 342(26): 1946-52.
23. Masferrer JL, Leahy KM, Koki A-T, Zweifel BS, Settle SL, Woerner BM, et al. Antiangiogenic and antitumor activities of cyclooxygenase-2 inhibitors. Cancer Res 2000; 60(5): 1306-11.
24. Achiwa H, Yatabe Y, Hida T, Kuroishi T, Kozaki K, Nakamura S, et al. Prognostic significance of elevated cyclooxygenase-2 expression in primary, resected lung adenocarcinomas. Clin Cancer Res 1999; 5(5): 1001-5.
25. Khuri FR, Wu H, Lee JJ, Kemp BL, Lotan R, Lippman SM, et al. Cyclooxygenase-2 overexpression is a marker of poor prognosis in stage I non-small cell lung cancer. Clin Cancer Res 2001; 7(4): 861-7.
26. Zhang S, Yu D. PI(3)king apart PTEN's role in cancer. Clin Cancer Res 2010; 16(17): 4325-30.
27. Vasudevan KM, Gurumurthy S, Rangnekar VM. Suppression of PTEN expression by NFkappaB prevents apoptosis. Mol Cell Biol 2004; 24(3): 1007-21.
28. Fortin, S. Polyunsaturated fatty acid monoglycerides, derivatives, and uses thereof. CA2672513 (2008).
29. Schreck R, Meier B, Männel DN, Dröge W, Baeuerle PA. Dithiocarbamates as potent inhibitors of nuclear factor kappa B activation in intact cells. J Exp Med 1992; 175(5): 1181-94.
30. Woods JS, Ellis ME, Dieguez-Acuña FJ, Corral J. Activation of NF-kappaB in normal rat kidney epithelial (NRK52E) cells is mediated via a redox-insensitive, calcium-dependent pathway. Toxicol Appl Pharmacol 1999; 154(3): 219-27.
31. Morin C, Sirois M, Echave V, Gomes MM, Rousseau E. EET displays anti-inflammatory effects in TNF-alpha stimulated human bronchi: Putative role of CPI-17. Am J Respir Cell Mol Biol 2008; 38(2): 192-201.
32. Morin C, Sirois M, Echave V, Albadine R, Rousseau E. 17, 18-epoxyeicosatetraenoic acid targets PPARgamma and p38 mitogenactivated protein kinase to mediate its anti-inflammatory effects in the lung: Role of soluble epoxide hydrolase. Am J Respir Cell Mol Biol 2010; 43(5): 564-75.
33. Reagan-Shaw S, Nihal M, Ahmad N. Dose translation from animal to human studies revisited. FASEB J 2008; 22(3): 659-61.
34. Gagne S, Crane S, Huang Z, Li CS, Bateman KP, Levesque JF. Rapid measurement of deuterium-labeled long-chain fatty acids in plasma by HPLC-ESI-MS. J Lipid Res 2007; 48(1): 252-9.
35. Morin C, Fortin S, Cantin AM, Rousseau E. Docosahexaenoic acid derivative prevents inflammation and hyperreactivity in lung: Implication of PKC-Potentiated inhibitory protein for heterotrimeric myosin light chain phosphatase of 17 kD in asthma. Am J Respir Cell Mol Biol 2011; 45(2): 366-75.
36. Hardman WE, Moyer MP, Cameron IL. Dietary fish oil sensitizes A549 lung xenografts to doxorubicin chemotherapy. Cancer Lett 2000; 151(2): 145-51.
37. Karin M, Cao Y, Greten FR, Li ZW. NFkappaB in cancer: From innocent bystander to major culprit. Nat Rev Cancer 2002; 2(4): 301-10.
38. Kim KM, Lee YJ. Amiloride augments TRAIL-induced apoptotic death by inhibiting phosphorylation of kinases and phosphatases associated with the P13K-Akt pathway. Oncogene 2005; 24(3): 355-66.
39. Li J, Jia H, Xie L, Wang X, He H, Lin Y, et al. Association of constitutive nuclear factor-kappaB activation with aggressive aspects and poor prognosis in cervical cancer. Int J Gynecol Cancer 2009; 19(8): 1421-6.
40. Karin M, Greten FR. NFkappaB: Linking inflammation and immunity to cancer development and progression. Nat Rev Immunol 2005; 5(10): 749-59.
41. Jin X, Wang Z, Qiu L, Zhang D, Guo Z, Gao Z, et al. Potential biomarkers involving IKK/RelA signal in early stage non-small cell lung cancer. Cancer science 2008; 99(3): 582-9.
42. Grimes KR, Warren GW, Fang F, Xu Y, St Clair WH. Cyclooxygenase-2 inhibitor, nimesulide, improves radiation treatment against non-small cell lung cancer both in vitro and in vivo. Oncol Rep 2006; 16(4): 771-6.
43. Mao JT, Cui X, Reckamp K, Liu M, Krysan K, Dalwadi H, et al. Chemoprevention strategies with cyclooxygenase-2 inhibitors for lung cancer. Clin Cancer Res 2005; 7(1): 30-9.
44. Marsit CJ, Zheng S, Aldape K, Hinds PW, Nelson HH, Wiencke JK, et al. PTEN expression in non-small-cell lung cancer: Evaluating its relation to tumor characteristics, allelic loss, and epigenetic alteration. Human Pathol 2005; 36(7): 768-76.
45. Soria JC, Lee H-Y, Lee JI, Wang L, Issa JP, Kemp BL, et al. Lack of PTEN expression in non-small cell lung cancer could be related to promoter methylation. Clin Cancer Res 2002; 8(5): 1178-84.
46. Tang JM, He QY, Guo RX, Chang XJ. Phosphorylated Akt overexpression and loss of PTEN expression in non-small cell lung cancer confers poor prognosis. Lung Cancer 2006; 51(2): 181-91.
47. Kohno T, Takahashi M, Manda R, Yokota J. Inactivation of the PTEN/MMAC1/TEP1 gene in human lung cancers. Gene Chromosome Canc 1998; 22(2): 152-6.
48. Schley PD, Jijon HB, Robinson LE, Field CJ. Mechanisms of omega-3 fatty acid-induced growth inhibition in MDA-MB-231 human breast cancer cells. Breast Cancer Res Treat 2005; 92(2): 187-95.
49. Sauer LA, Dauchy RT. The effect of omega-6 and omega-3 fatty acids on 3H-thymidine incorporation in hepatoma 7288CTC perfused in situ. Br J Cancer 1992; 66(2): 297-303.
50. Sauer LA, Dauchy RT, Blask DE. Mechanism for the antitumor and anticachectic effects of n-3 fatty acids. Cancer Res 2000; 60(18): 5289-95.
51. Hajjaji N, Schubnel V, Bougnoux P. Determinants of DHA incorporation into tumor tissue during dietary DHA supplementation. Lipids 2011; 46(11): 1063-9.
52. Yam D, Peled A, Shinitzky M. Suppression of tumor growth and metastasis by dietary fish oil combined with vitamins E and C and cisplatin. Cancer Chemother Pharmacol 2001; 47(1): 34-40.
53. de Bravo MG, de Antueno RJ, Toledo J, De Tomas ME, Mercuri OF, Quintans C. Effects of an eicosapentaenoic and docosahexaenoic acid concentrate on a human lung carcinoma grown in nude mice. Lipids 1991; 26(11): 866-70.
54. Mernitz H, Lian F, Smith D-E, Meydani SN, Wang XD. Fish oil supplementation inhibits NNK-induced lung carcinogenesis in the A/J mouse. Nutr Cancer 2009; 61(5): 663-9.
55. Zhang J, Temme EH, Kesteloot H. Fish consumption is inversely associated with male lung cancer mortality in countries with high levels of cigarette smoking or animal fat consumption. Int J Epidemiol 2000; 29(4): 615-21.
56. Veierod MB, Laake P, Thelle DS. Dietary fat intake and risk of lung cancer: A prospective study of 51, 452 Norwegian men and women. Eur J Cancer Prev 1997; 6(6): 540-9.
57. Takezaki T, Inoue M, Kataoka H, Ikeda S, Yoshida M, Ohashi Y, et al. Diet and lung cancer risk from a 14-year population-based prospective study in Japan: with special reference to fish consumption. Nutr Cancer 2003; 45(2): 160-7.
58. Jump DB. Dietary polyunsaturated fatty acids and regulation of gene transcription. Curr Opin Lipidol 2002; 13(2): 155-64.
59. Calder PC. Fatty acids and gene expression related to inflammation. Nestle Nutr Workshop Ser Clin Perform Programme 2002; 7: 19-36.
60. Jia Q, Shi Y, Bennink MB, Pestka JJ. Docosahexaenoic acid and eicosapentaenoic acid, but not alpha-linolenic acid, suppress deoxynivalenol-induced experimental IgA nephropathy in mice. J Nutr 2004; 134(6): 1353-61.
61. Okuyama H, Kobayashi T, Watanabe S. Dietary fatty acids--the N-6/N-3 balance and chronic elderly diseases. Excess linoleic acid and relative N-3 deficiency syndrome seen in Japan. Prog Lipid Res 1996; 35(4): 409-57.
62. Xia S, Lu Y, Wang J, He C, Hong S, Serhan CN, et al. Melanoma growth is reduced in fat-1 transgenic mice: Impact of omega-6/omega-3 essential fatty acids. Proc Natl Acad Sci USA 2006; 103(33): 12499-504.
63. Xia SH, Wang J, Kang JX. Decreased n-6/n-3 fatty acid ratio reduces the invasive potential of human lung cancer cells by downregulation of cell adhesion/invasion-related genes. Carcinogenesis 2005; 26(4): 779-84.
64. Kinsella JE, Lokesh B, Stone RA. Dietary n-3 polyunsaturated fatty acids and amelioration of cardiovascular disease: Possible mechanisms. Am J Clin Nutr 1990; 52(1): 1-28.
65. Fortin, S. Polyunsaturated fatty acid monoglycerides, derivatives, and uses thereof. CA2677670 (2010) & US8119690 (2011).
66. Fortin, S. Compositions comprising polyunsaturated fatty acid monoglycerides or derivatives thereof and uses thereof. US819690 (2012) & US8222295 (2012).
67. Fotini, S. T. Natural marine source phospholipids comprising polyunsaturated fatty acids and their applications. US8030348 (2012).
68. Firshein, R. N. Method of treating cancer using alkylglycerols in conjunction with chemotherapy. US6121245 (2000).
69. Kazuyoshi, Y., Masaaki, I., Eiji, A., Hiroyuki, T. Metastatiscontrolling agent. JP9025231 (1997).
70. Zheng, X. Cytotropic heterogeneous molecular lipids (CHML), method of preparation, and methods of treating patients with multiple cancers. US7759332 (2010).
71. Iwao, O. Taxoid-fatty acid conjugates and pharmaceutical compositions thereof. US7820839 (2010).
72. Webb, N. L., Bradley, M. O., Anthony, F., Fisher, M. Fatty acidanticancer conjugates and uses thereof. US7235583 (2007).
73. Yuqiang, W. Anticancer conjugates of camptothecin and unsaturated fatty acids. US6759416 (2004).
74. Shashoua, V. E., Swindell, C. E., Webb, N. L., Bradley, M. O. DHApharmaceutical agent conjugates to improve tissue selectivity. US6602902 (2003).
75. Shashoua, V. E., Swindell, C. S., Webb, N. L., Bradley, M. O. DHApharmaceutical agent conjugates of taxanes. US5795909 (1998).
76. Troiani T, Vecchione L, Martinelli E, Capasso A, Costantino S, Ciuffreda LP, et al. Intrinsic resistance to selumetinib, a selective inhibitor of MEK1/2, by cAMP-dependent protein kinase A activa tion in human lung and colorectal cancer cells. Br J Cancer 2012; 106(10): 1648-59.
77. Correale P, Botta C, Basile A, Pagliuchi M, Licchetta A, Martellucci I, et al. Phase II trial of bevacizumab and dose/dense chemotherapy with cisplatin and metronomic daily oral etoposide in advanced non-small-cell-lung cancer patients. Cancer Biol Ther 2011; 12(2): 112-8.
78. Correale P, Remondo C, Carbone SF, Ricci V, Migali C, Martellucci I, et al. Dose/dense metronomic chemotherapy with fractioned cisplatin and oral daily etoposide enhances the antiangiogenic effects of bevacizumab and has strong antitumor activity in advanced non-small-cell-lung cancer patients. Cancer Biol Ther 2010; 9(9): 685-93.
79. Correale P, Marra M, Remondo C, Migali C, Misso G, Arcuri FP, et al. Cytotoxic drugs up-regulate epidermal growth factor receptor (EGFR) expression in colon cancer cells and enhance their susceptibility to EGFR-targeted antibody-dependent cell-mediatedcytotoxicity (ADCC). Eur J Cancer 2010; 46(9): 1703-11.
80. Hajjaji N, Bougnoux P. Selective sensitization of tumors to chemotherapy by marine-derived lipids: A review. Cancer Treat Rev 2012; 39(5): 473-88.
81. Murphy RA, Mourtzakis M, Chu QS, Baracos VE, Reiman T, Mazurak VC. Supplementation with fish oil increases first-line chemotherapy efficacy in patients with advanced nonsmall cell lung cancer. Cancer 2011; 117(16): 3774-80.
82. Bougnoux P, Hajjaji N, Ferrasson MN, Giraudeau B, Couet C, Le Floch O. Improving outcome of chemotherapy of metastatic breast cancer by docosahexaenoic acid: A phase II trial. Br J Cancer 2009; 101(12): 1978-85.
83. Morin C, Fortin S, Rousseau E. [3 and 36 CYP450 Eicosanoid Derivatives: Key Lipid Mediators in the Regulation of Pulmonary Hypertension. Pulmonary Hypertension-From Bench Research to Clinical Practice. 2011; 6-16.
84. 2+ sensitivity in human pulmonary arteries. Am J Physiol Heart Circ Physiol 2011; 301(4): H1311-8.
85. Caraglia M, Marra M, Misso G, Lamberti M, Salzano G, De Rosa G, et al. Tumour-specific uptake of anti-cancer drugs: The future is here. Curr Drug Metab 2012; 13(1): 4-21.
86. Caraglia M, De Rosa G, Salzano G, Santini D, Lamberti M, Sperlongano P, et al. Nanotech revolution for the anti-cancer drug delivery through blood-brain-barrier. Curr Cancer Drug Targets 2012; 12(3): 186-96.